STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Sep. 30, 2018		28,034,487
Balance, amount at Sep. 30, 2018	$ 916	$ 280,346	$ 331,312,184	$ (331,591,614)
Warrant exercises, shares		6,677,519
Warrant exercises, amount	18,106,617	$ 66,775	18,039,842	0
401(k) contributions paid in common stock, shares		30,996
401(k) contributions paid in common stock, amount	$ 143,878	$ 310	143,568	0
Stock issued to nonemployees for service, shares	199,977	199,977
Stock issued to nonemployees for service, amount	$ 878,588	$ 1,999	876,589	0
Equity based compensation - employees, shares		(7,500)
Equity based compensation - employees, amount	4,428,174	$ (75)	4,428,249	0
Stock option exercises, shares		65,997
Stock option exercises, amount	150,482	$ 660	149,822	0
Purchase of stock by officers and directors, shares		45,205
Purchase of stock by officers and directors, amount	291,997	$ 452	291,545	0
Stock issuance costs	(132,345)	$ 0	(132,345)	0
Shares issued for settlement of clinical research costs, shares		185,095
Shares issued for settlement of clinical research costs, amount	3,400,000	$ 1,851	3,398,149	0
Net loss	(22,134,640)	$ 0	0	(22,134,640)
Balance, shares at Sep. 30, 2019		35,231,776
Balance, amount at Sep. 30, 2019	5,133,667	$ 352,318	358,507,603	(353,726,254)
Warrant exercises, shares		1,711,873
Warrant exercises, amount	15,144,240	$ 17,118	15,127,122	0
401(k) contributions paid in common stock, shares		13,870
401(k) contributions paid in common stock, amount	$ 163,340	$ 139	163,201	0
Stock issued to nonemployees for service, shares	79,950	79,950
Stock issued to nonemployees for service, amount	$ 972,667	$ 799	971,868	0
Equity based compensation - employees, amount	10,112,968	$ 0	10,112,968	0
Stock option exercises, shares		99,740
Stock option exercises, amount	338,328	$ 998	337,330	0
Purchase of stock by officers and directors, shares		20,512
Purchase of stock by officers and directors, amount	184,990	$ 205	184,785	0
Stock issuance costs	(787,723)	$ 0	(787,723)	0
Shares issued for settlement of clinical research costs, shares		150,000
Shares issued for settlement of clinical research costs, amount	1,769,500	$ 1,500	1,768,000	0
Net loss	(30,255,244)	$ 0	0	(30,255,244)
Adoption of new accounting principle (ASC 842)	2,146,195			2,146,195
Proceeds from the sale of common stock, shares		1,422,429
Proceeds from the sale of common stock, amount	13,992,439	$ 14,225	13,978,214	0
Warrant issuances	805,753	0	805,753	0
Modification of warrants	5,554	$ 0	5,554	0
Balance, shares at Sep. 30, 2020		38,730,150
Balance, amount at Sep. 30, 2020	$ 19,726,674	$ 387,302	$ 401,174,675	$ (381,835,303)